Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Pediatric Pulmonology
|
October 12, 2001
Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents
J Rosenecker, I Eichler, H Bärmeier, et al.
Chronobiology International
|
January 1, 1987
On the daily variation in the beta-receptor-adenylate cyclase-cAMP-phosphodiesterase system in rat forebrain
B Lemmer, H Bärmeier, S Schmidt, et al.
Endocrinology and Metabolism Clinics of North America
|
September 1, 1991
Autoimmunity of diabetes
A Lernmark, H Bärmeier, S Dube, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
March 9, 2005
Prospective evaluation of emerging bacteria in cystic fibrosis
G Steinkamp, B Wiedemann, E Rietschel, et al.
Autoimmunity
|
January 1, 1992
Quantitative analysis of islet glutamic acid decarboxylase p64 autoantibodies in insulin-dependent diabetes mellitus
H Bärmeier, J Ahlmén, M Landin-Olsson, et al.
Infection
|
July 8, 2000
Optimal tobramycin dosage in patients with cystic fibrosis--evidence for predictability based on previous drug monitoring
K Bartel, T Habash, S Lugauer, et al.
Diabetologia
|
October 1, 1991
Risk for developing type 1 (insulin-dependent) diabetes mellitus and the presence of islet 64K antibodies
H Bärmeier, D K McCulloch, J L Neifing, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 1, 1991
Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10
A E Karlsen, W A Hagopian, C E Grubin, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Pediatric Pulmonology
|
October 12, 2001
Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents
J Rosenecker, I Eichler, H Bärmeier, et al.
Chronobiology International
|
January 1, 1987
On the daily variation in the beta-receptor-adenylate cyclase-cAMP-phosphodiesterase system in rat forebrain
B Lemmer, H Bärmeier, S Schmidt, et al.
Endocrinology and Metabolism Clinics of North America
|
September 1, 1991
Autoimmunity of diabetes
A Lernmark, H Bärmeier, S Dube, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
March 9, 2005
Prospective evaluation of emerging bacteria in cystic fibrosis
G Steinkamp, B Wiedemann, E Rietschel, et al.
Autoimmunity
|
January 1, 1992
Quantitative analysis of islet glutamic acid decarboxylase p64 autoantibodies in insulin-dependent diabetes mellitus
H Bärmeier, J Ahlmén, M Landin-Olsson, et al.
Infection
|
July 8, 2000
Optimal tobramycin dosage in patients with cystic fibrosis--evidence for predictability based on previous drug monitoring
K Bartel, T Habash, S Lugauer, et al.
Diabetologia
|
October 1, 1991
Risk for developing type 1 (insulin-dependent) diabetes mellitus and the presence of islet 64K antibodies
H Bärmeier, D K McCulloch, J L Neifing, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 1, 1991
Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10
A E Karlsen, W A Hagopian, C E Grubin, et al.
Page
of 1